THE Generic and Biosimilar Medicines Association (GBMA) will continue its expansion with JAMP Pharma Australia named as its newest Tier 5 Affiliate member.
This entry-level membership is designed for manufacturers, industry associations, and patient groups with shared goals.
The GBMA's members aim to deliver significant savings to the Federal Government, with over 900 generic and biosimilar brands available, representing 80% of the total generic volume on the PBS.
GBMA CEO, Marnie Peterson, highlighted the addition of JAMP Pharma comes at a pivotal time for the association.
"Our members are striving to help Australians mitigate rising living costs while protecting patients from avoidable medicine shortages," she said.
Under the GBMA's five-year Strategic Agreement with the Federal Government, members have collectively invested over $200 million in infrastructure and stock procurement, creating a buffer of four to six months' worth of medicines onshore.
This effort equates to more than 52 million additional packets, or 17,000 pallets of essential medicines, ensuring equitable access for all Australians.
JAMP Pharma Country Head Mary Dimitratos emphasised the company's alignment with GBMA's patient-driven policies and sustainability initiatives.
"We look forward to actively working with the GBMA and its stakeholders to reinforce access to affordable, high-quality medicines, improve supply, and support policy reforms benefiting all Australians," Dimitratos commented.
The Sydney based JAMP Pharma Australia, part of the international group, stated its commitment to providing a steady supply of affordable medicines, and has plans to launch a range of generic products in the country. JG
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Jul 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Jul 24
